Jun. 4 at 11:18 AM
$NYMXF Now that our Leader has finally, although about 2 years late, admitted the UK Rejected the Application I’m so glad we listen to Dr A and Rejected the Ascella opportunity.
Ascella would have invested Millions of Dollars, redone the Trials to FDA Standards and Requirements, had 2 Board Seats which would have negatively impacted our leader Dr A, had various world wide Jurisdictions demanding drug applications for approval and Nymox would probably be
$50.00 priced stock now.
We are so much better off now with 8 Rejections.
Dr A has such a great idea and I’m so excited we are starting a new round of submitting poor quality applications starting with the FDA.
You Dr A lovers are amazing.